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Abstract
A major defect contributing to impaired insulin action in human
obesity is reduced glucose transport activity in skeletal muscle.
This study was designed to determine whether the improve-
ment in whole body glucose disposal associated with weight
reduction is related to a change in skeletal muscle glucose trans-
port activity and levels of the glucose transporter protein
GLUT4. Seven morbidly obese (body mass index = 45.8±2.5,
mean ± SE) patients, including four with non-insulin-depen-
dent diabetes mellitus (NIDDM), underwent gastric bypass
surgery for treatment of their obesity. In vivo glucose disposal
during a euglycemic clamp at an insulin infusion rate of 40
mU/mi per min was reduced to 27% of nonobese controls (P
< 0.01) and improved to 78% of normal after weight loss of
43.1±3.1 kg (P < 0.01). Maximal insulin-stimulated glucose
transport activity in incubated muscle fibers was reduced by
_ 50% in obese patients at the time of gastric bypass surgery
but increased twofold (P < 0.01) to 88% of normal in five sepa-
rate patients after similar weight reduction. Muscle biopsies
obtained from vastus lateralis before and after weight loss re-
vealed no significant change in levels of GLUT4 glucose trans-
porter protein. These data demonstrate conclusively that insu-
lin resistance in skeletal muscle of mobidly obese patients with
and without NIDDM cannot be causally related to the cellular
content of GLUT4 protein. The results further suggest that
morbid obesity contributes to whole body insulin resistance
through a reversible defect in skeletal muscle glucose transport
activity. The mechanism for this improvement may involve en-
hanced transporter translocation and/or activation. (J. Clin.
Invest. 1992. 89:701-705.) Key words: insulin resistance * obe-
sity * glucose disposal * noninsulin-dependent diabetes mellitus
* glucose metabolism
Introduction
Peripheral insulin resistance is a primary disorder in both obe-
sity and non-insulin-dependent diabetes mellitus (NIDDM)'
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1. Abbreviations used in this paper: BMI, body mass index; NIDDM,
non-insulin-dependent diabetes mellitus; TBS, Tris-buffered saline.
(1-3). This appears to be due at least in part to a defect in
skeletal muscle, the major site of whole body insulin-depen-
dent glucose disposal (2-4). Using a novel in vitro human mus-
cle preparation, we recently demonstrated that insulin-stimu-
lated glucose transport was severely decreased by 50% in
muscle of morbidly obese patients with or without NIDDM
(5). Although the primary defect(s) responsible for the insulin
resistance is still unknown, one possible candidate for this de-
fect is the glucose transporter, since glucose transport is the
rate-limiting step for glucose utilization in muscle (6, 7).
The glucose transport response in insulin-sensitive tissues
such as muscle and fat is predominantly mediated by the
unique glucose transporter isoform GLUT4 (8). Garvey et al.
(9) recently demonstrated that the cellular insulin resistance in
adipocytes from obese and obese-NIDDM patients is accompa-
nied by a 40-80% depletion of GLUT4 glucose transporter
protein. However, the mechanism underlying the severe defect
in glucose transport activity in skeletal muscle is much less
clear. Pederson et al. (10) and Handberg et al. ( 11) reported no
significant change in levels of muscle GLUT4 protein in vastus
lateralis of obese NIDDM patients compared with lean con-
trols. On the other hand, our group recently reported that
GLUT4 protein is decreased by - 20% in both rectus abdom-
inis and vastus lateralis muscles in morbidly obese patients,
with or without NIDDM (12). This discrepancy may be due in
part to the heterogeneity of the obesity syndrome, as well as a
large biological variability in muscle GLUT4 protein found in
normal subjects (10-12).
Given that decreased glucose transport is a major mecha-
nism underlying insulin resistance, we sought to determine
whether muscle GLUT4 transporter protein contributes to the
insulin resistance of skeletal muscle by examining levels ofglu-
cose transporter protein GLUT4 in the same patients before
and after a period ofweight loss, which has been shown to be an
effective means of improving peripheral glucose disposal (13-
16). In addition to muscle glucose transporter GLUT4, we ex-
amined whole body glucose disposal and glucose transport ac-
tivity in muscle from patients after weight loss to permit com-
parisons of changes in muscle glucose transporter protein with
changes in insulin action in vivo and muscle transport activity
in vitro.
Methods
Materials. 2-[l,2-3H(N)]deoxy-D-glucose (30.2 Ci/mmol) and [U-'4C]-
D-sorbitol (150-250 mCi/mmol) were obtained from Du Pont-NEN
(Boston, MA). Reagents for PAGE were purchased from Bio-Rad Labo-
ratories (Richmond, CA). An affinity-purified polyclonal antibody spe-
cific for a carboxy-terminal synthetic peptide (30 amino acids) for
GLUT4 (8) was generously supplied by Dr. Lawrence Sleiker (Eli Lilly
Research Laboratories, Indianapolis, IN). Unless otherwise stated,
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all other reagents were purchased from Sigma Chemical Co. (St.
Louis, MO).
Subjects. Subject characteristics are listed in Table I. Seven mor-
bidly obese patients (body mass index [BMI] > 40 kg/m2) scheduled for
gastric bypass surgery were studied. Of these patients, four were classi-
fied as having NIDDM and three were classified as nondiabetic, ac-
cording the criteria established by the National Diabetes Data Group
(17). None of the subjects had any disease other than diabetes and/or
obesity and were weight stable for 2 2 mo before entry into the study.
Of the four diabetics, two were on insulin and two were being treated
with oral agents. The experimental protocol was explained to each sub-
ject, and informed consent was obtained. The project was approved by
the East Carolina University Policy and Review Committee on Human
Research.
Euglycemic clamp and muscle biopsies. In vivo glucose disposal
was assessed and muscle biopsies obtained I mo before gastric bypass
surgery and again after a stable body weight was achieved, - 12 mo
after gastric bypass surgery. After surgery all patients were followed at
6-8-wk intervals for weighing and dietary counseling. A plateau in
weight was declared when three consecutive weights varied by > 1 kg.
2 wk before the study diabetic patients were withdrawn from therapy
with consent and were followed on an outpatient basis. Subjects re-
ceived a weight-maintaining diet containing 50% of total calories as
carbohydrates, 30% as fat, and 20% as protein for 3 d before each
clamp. Subjects were admitted to the Outpatient Clinical Research
Unit of the East Carolina University School of Medicine at 8:00 a.m.
after an overnight fast. A 50-100-mg muscle sample was obtained from
the vastus lateralis muscle using the percutaneous muscle biopsy tech-
nique as described previously (12). The muscle tissue was rinsed and
dissected free of connective tissue, quick frozen on dry ice, and stored
at -70° C until analysis for GLUT4 protein. The subjects then under-
went a 2-h hyperinsulinemic euglycemic clamp (without radioactivity)
to determine in vivo glucose disposal as described in detail previously
(18, 19). A continuous insulin infusion rate of40 mU/m2 per min was
used and plasma glucose was maintained between 80 and 90 mg/dl
throughout the test by a variable infusion of20% dextrose. The glucose
disposal rate (M) = mg/m2 per min was calculated using the exogenous
glucose infusion rate during the final 30 min of euglycemia.
Analytical methods. Plasma glucose was analyzed by the glucose
oxidase method (glucose analyzer II; Beckman Instruments Inc., Ful-
lerton, CA). Insulin was analyzed by double antibody radioimmunoas-
say using a kit supplied by Cambridge Diagnostics (Billerica, MA) ac-
cording to the method of Desbuquois and Aurbach (20). Glycosylated
hemoglobin was determined in heparinized blood using the fast hemo-
globin test system kit (Isolab, Inc., Akron, OH).
2-deoxy-D-glucose transport in human musclefiber strips. Glucose
transport activity was determined in rectus abdominis muscle obtained
from seven morbidly obese patients during gastric bypass surgery for
the treatment of their obesity (21) and from five former gastric bypass
patients undergoing elective abdominal surgery, as described previ-
ously (5). After an overnight fast, general anesthesia was induced with a
short-acting barbiturate and maintained by fentanyl and N20-02 mix-
ture. Only saline was given intravenously before the biopsy. After ex-
posing the rectus abdominis, a 3 X 2 X 2 cm biopsy was clamped,
excised, and quickly transported to the laboratory in oxygenated
Krebs-Henseleit buffer. Muscle fiber strips weighing 40-80 mg were
teased from the muscle and a smaller clamp (2 cm) was placed on the
muscle fiber strip before it was cut free. Muscles were incubated in 4.0
ml of medium consisting of Krebs-Henseleit buffer, 1% bovine serum
albumin, 1.0 mM pyruvate, at 0, 1 X 10', and 1 x 10' M insulin.
Transport was measured in the presence of 5 mM 2-deoxy-D-glucose
for 60 min as described previously (5).
Analysis ofglucose transporter protein. To minimize any contribu-
tion of interassay variability, muscle samples from each subject's pre-
and post-weight reduction biopsies were prepared and analyzed for
GLUT4 protein in the same assay. The procedufes for quantifying
GLUT4 are described here and elsewhere in detail (12, 19). Muscle
biopsies were homogenized (Polytron; Brinkmann Instruments, Inc.,
Westbury, NY) in 2 ml ofcold (4° C) buffer (pH 7.4) containing 25 mM
Hepes, 25 mM benzamidine, 4 mM EDTA, 0.5 mM PMSF, and 1 ,uM
each of leupeptin, pepstatin, and aprotinin. To isolate cellular mem-
branes, samples were centrifuged at 150,000 g for 1 h at 4° C. The
resulting pellet was rinsed and resuspended (Polytron) in cold buffer.
Triton was added to each resuspension to give a final concentration of
1%. The samples were allowed to sit on ice for 1.5 h to solubilize the
membrane-bound protein. After a final spin (150,000 g, 1 h, 4° C), the
supernatant was removed and used for Western analysis. Duplicate
samples containing 50 gg protein (BCA procedure; Pierce Chemical
Co., Rockford, IL) were mixed overnight at 4° C with Laemmli sample
buffer (22) containing 2.5% dithiothreitol and 1% SDS. Proteins were
separated by SDS-PAGE under reducing conditions on an 8% resolving
gel and transferred to Immobilon membrane (Millipore Corp., Bed-
ford, MA) by electrotransfer (500 mA, 2 h). The membrane was
blocked for 2 h in 5% Carnation low-fat instant milk in Tris-buffered
saline (TBS-blotto), followed by incubation for 16 h at 4° C in polyclo-
nal antibody (1 gg/ml in TBS-blotto) specific for the GLUT4 trans-
porter isoform. The membrane was washed in TBS/TBS-Tween and
incubated 1 h at 25° C in 50 ml TBS-blotto containing donkey anti-
rabbit antibody conjugated to horseradish peroxidase (1:4,000).
GLUT4 was visualized using an enhanced chemiluminescence detec-
tion system (Amersham, Corp., Arlington Heights, IL). Membranes
were washed in TBS/TBS-Tween and incubated for 1 min in detection
reagent (luminol + H202), followed by exposure to Hyperfilm (Amer-
sham Corp.) for 10-30 s. The resulting films were analyzed by scanning
densitometry.
Statistical analysis. All data are given as mean ± SEM. Paired t test
was used to determine differences between the same patients before
and after weight loss. Glucose transport in five separate morbidly obese
Table I. Clinical and Metabolic Characteristics
Weight BMI Glucose Insulin HbAjC
Patient Sex Age Height Before After Before After Before After Before After Before After
n M/F yr cm kg kg/rM2 mg/dl yU /m1I
1 F 45 168 106.8 72.6 40.3 27.5 103 85 28.0 12.6 5.0 5.4
2 F 53 164 112.0 69.0 40.6 25.8 103 92 23.0 12.6 5.8 5.4
3 M 40 188 186.9 129.5 52.9 35.5 103 88 31.0 11.7 4.6 4.7
4 F 32 160 107.0 68.9 41.6 26.9 128* 71 25.0 5.3 7.1 5.2
5 F 40 158 139.0 91.2 55.6 39.7 138* 88 23.0 12.2 11.1 5.8
6 F 40 162 122.9 81.4 46.9 31.1 122* 81 25.0 6.0 7.1 5.4
7 F 43 175 132.0 92.1 43.2 30.4 149* 85 33.0 7.0 8.4 5.5
Mean 6F/lM 41.8 168 129.5 83.4* 45.8 30.9t 121 84t 26.8 9.6* 7.0 5.3t
±SE ±2.6 ±4 ±11.5 ±8.7 ±2.5 ±2.1 ±8 ±3 ±1.6 ±1.4 ±0.9 ±0.1
* Non-insulin-dependent diabetic; * significantly reduced after weight loss, P < 0.01.
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patients after weight loss was compared with the obese patients and
previously published data on nonobese controls (5) using one-way anal-
ysis of variance. Newman-Keuls post-hoc testing was used to deter-
mine significant differences between groups.
Results
The subject characteristics are presented in Table I. The mean
weight ofthe group fell from 129.5±11.5 to 83.4±8.7 kg, mean
± SE. (P < 0.01), resulting in a mean weight loss of43.1±2.3 kg
(range, 34-57 kg) or 36% of initial mean body weight. Like-
wise, the BMI, which correlates well with the degree of obesity,
fell from 45.8±2.5 to 30.9±2.1 kg/M2 (P < 0.01). Upon enter-
ing the study, obese nondiabetics had normal glucose toler-
ance, whereas the obese NIDDM patients had fasting hypergly-
cemia. After weight reduction, fasting plasma glucose was nor-
malized in diabetic patients from 134±7 to 81±4 mg/dl (P
< 0.01). Glycosylated hemoglobin decreased from 7.9±2.2 to
5.5±0.3% (P < 0.01) in diabetic patients after weight loss. Sig-
nificant reductions in fasting insulin were observed in all obese
patients as a result of weight loss (from 26.8±1.6 to 9.6±1.4
jiU/ml, P < 0.01).
To determine the effect of weight loss on in vivo glucose
disposal, a euglycemic clamp was performed in all subjects be-
fore and after weight loss at an insulin infusion rate of 40 mU/
m per min (Fig. 1). Insulin levels during the clamp averaged
_ 100 ,uU/ml before and after weight loss. Glucose disposal
increased significantly by threefold from 84±5 to 252±32 mg/
m2per min after weight loss (P < 0.01). For comparison pur-
poses, glucose disposal in nonobese nondiabetic patients at sim-
ilar levels of insulinemia and glycemia in our laboratory aver-
age 322±19.6 mg/M2 per min. Thus, the glucose disposal rate
was 27% of normal in obese patients initially and improved to
78% of normal after weight loss.
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Figure 1. Effect of weight loss on whole body insulin-stimulated glu-
cose disposal rates. Individual and mean glucose disposal rates during
40 mU/M2 per min insulin infusion rate euglycemic clamp performed
before (o) and after weight loss (4). For comparison, glucose disposal
rate in nonobese nondiabetics is 322±19.6 mg/M2 per min (mean
± SEM) under comparable euglycemic and hyperinsulinemic condi-
tions.
Effect ofweight loss on 2-deoxyglucose transport. For ethi-
cal reasons, we were unable to obtain rectus muscle from the
same patients after weight loss. However, we were able to study
glucose transport activity in rectus abdominis muscle from a
similar group of patients undergoing revision (n = 2), hernia
repair (n = 2), or abdominoplasty (n = 1) 15-24 mo after gas-
tric bypass surgery. These patients had stabilized in body
weight after a similar weight loss of 27-49 kg (BMI = 31.3±2.8
kg/M2). As shown in Fig. 2, maximal insulin-stimulated glu-
cose transport activity was increased 1.9±0.3-fold over basal
(range, 1.3-2.9) in patients after weight loss (P < 0.01). Insulin-
stimulated glucose transport activity in morbidly obese pa-
tients at the time of gastric bypass was 50% of nonobese
nondiabetic patients, published previously (5), and these data
are now presented together with our previous work. The values
for glucose transport in patients after weight loss reveal an ap-
proximately twofold increase in maximal glucose transport ac-
tivity from 25.3±3.3 to 48.2±7.3 nmol/g dry wt per min (P
< 0.01). Thus, weight loss restored maximal insulin-stimulated
skeletal muscle glucose transport activity to 88% of normal,
nonobese patients. Lack of tissue prevented us from perform-
ing a complete insulin dose-response curve in incubated mus-
cle; however, at a single submaximal concentration of insulin
(10-' M) glucose transport activity increased significantly from
25.3±3.3 to 37.3±5.1 nmol/g dry wt per min (P < 0.05). This
value corresponds to 83% of nonobese nondiabetic subjects at
the same insulin concentration (data not shown).
To determine whether the improvement in insulin-stimu-
lated glucose transport capacity could be accounted for by in-
creased levels of the insulin-sensitive glucose transporter pro-
tein GLUT4, muscle biopsies were obtained from vastus later-
alis muscle in the gastric bypass patients before and after weight
loss. Identical amounts of total membrane protein were size
fractionated by SDS-PAGE, transferred to nitrocellulose mem-
brane, and detected using an affinity purified COOH-terminal
anti-GLUT4 antibody. Fig. 3 A shows a representative autora-
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Figure 2. 2-Deoxyglucose transport in muscle fiber strips from non-
obese subjects (BMI = 26.3±0.6 kg/M2), morbidly obese subjects with
normal glucose tolerance or NIDDM (BMI = 45.8±2.5 kg/M2), and
morbidly obese patients after weight loss (BMI = 31.3 ± 2.8 kg/mi2).
Muscle fiber strips were prepared as outlined previously (5) and rates
of 2-deoxyglucose transport measured under basal (0 insulin) condi-
tions and after 60 min of maximal insulin (O-7 M) stimulation.
*Significantly less than (P < 0.05) muscle from nonobese or post-
weight loss group (+ insulin). tValues for nonobese and obese (n = 5)
were taken from reference 5 for comparison.
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r levels in muscle in the with other investigators using a variety of in vivo and in vitro
t loss. In all subjects, techniques, have suggested that decreased glucose transport ac-
in. GLUT4 was quanti- tivity is a major defect contributing to impaired insulin action
es are shown in Fig. 3B. in human obesity (3, 6, 9, 23). In morbidly obese subjects pe-
I slightly in six of seven ripheral glucose disposal is markedly decreased compared with
nonsignificant decrease nonobese controls, and this may be due to the severe decrease
se transporter protein in muscle glucose transport activity found here and in our pre-
nbrane protein did not vious study (5).
mounts oftotal protein After weight loss of 36% initial body weight, glucose dis-
milar before and after posal during a hyperinsulinemic euglycemic clamp increased
g/mg tissue). markedly by threefold. This is consistent with previous studies
demonstrating that weight loss in obese and obese-NIDDM
subjects improves whole-body insulin sensitivity (13-15), as
well as maximal glucose disposal in obese-NIDDM patients
fl muscle is the primary after a lesser degree of weight loss ( 15). The current study re-
in resistance in human veals the cellular mechanisms underlying the improvement in
to be due in part to a the effect of insulin to stimulate peripheral glucose disposal.
n skeletal muscle, the With weight loss, maximal glucose transport activity in vitro in
lisposal. We (5), along skeletal muscle increased nearly twofold to levels 88% of
nonobese nondiabetic patients. Lack of tissue prevented us
from performing a complete insulin dose-response curve in
0 patients after weight loss. However, at 10-' M insulin we ob-
a & served a significant increase in glucose transport activity, which
suggests that insulin sensitivity, as well as responsiveness, im-
proved in human skeletal muscle after weight loss. Increased
GLUT4 insulin sensitivity has also been associated with physical train-ing (24, 25). Although daily activity levels may have increased,
an effect of exercise is unlikely, however, because none of the
subjects were involved in a regular endurance training pro-
gram. Although only one male subject was studied, his re-
sponse was in the same direction as in the female subject. An
increase in glucose transport activity has also been observed in
adipocytes after weight loss (15). Given that skeletal muscle is
responsible for > 80% of insulin-mediated glucose uptake in
vivo (26, 27), the present findings support the conclusion that
obesity contributes to whole body insulin resistance through a
reversible defect in skeletal muscle glucose transport activity.
The improvement in muscle glucose transport activity with
weight loss could be due to changes in the levels of glucose
transporter protein, or part of the signal transduction pathway
P~n~s. whereby insulin stimulates glucose transport. Garvey et al. (9)P-fl.3. demonstrated a 40-80% depletion in the insulin-sensitive glu-
cose transporter protein GLUT4 in adipocytes from patients
with obesity and NIDDM. Similar findings have also been re-
ported by Sinha et al. in obese patients with NIDDM (28).
However, the effects of insulin resistance on GLUT4 trans-
porter protein in human skeletal muscle appear to be some-
what controversial. Pederson et al. (10) and others (1 1, 29) have
reported no change in GLUT4 protein in vastus lateralis mus-
cle of obese and obese-NIDDM patients. However, we previ-
ously observed a 20% decrease in levels ofmuscle glucose trans-
AFTER porter protein GLUT4 in both rectus abdominis and vastuslateralis muscle in obese patients with and without NIDDM
unodetection of GLUT4 (12). Although this decrease likely contributes to the insulin
iscle. Muscle biopsies were resistance in these patients, the degree ofresistance in vivo or inter weight loss and crude vitro did not correlate well with the small changes observed inods. Identical quantities of muscle GLUT4 protein, which suggests factors other than the
ibjected to SDS-PAGE, level of glucose transporters regulate insulin responsiveness.
l portion (30 amino acids) Likewise, the slight decrease observed here in muscle GLUT4
represents an autoradio- protein in the same patients after weight loss was not reflected
Ltification by scanning den- by in vivo glucose uptake as measured by euglycemic clamp or
'LUT4 transporters ob- maximal glucose transport activity in isolated muscle. Taken
together, these results clearly show that impaired glucose trans-
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I
port activity in obesity cannot be causally related to the cellular
content ofGLUT4 protein in human skeletal muscle. Results
similar to these have been reported in muscle of obese and
obese-NIDDM rats (30-32).
The contribution ofan insulin receptor signalling defect to
the insulin resistance of obesity and NIDDM was investigated
by Freidenberg et al. (13), who found that weight loss reversed
the insulin receptor tyrosine kinase defect present in adipocytes
from obese-NIDDM patients. A similar defect exists in skeletal
muscle of the obese and obese-NIDDM patients studied here
(33) and elsewhere (34, 35). Although the regulation ofglucose
transport activity probably involves factors other than just acti-
vation of tyrosine kinase, it is likely that this or some other
defect of insulin signaling more distal to the insulin receptor is
responsible for decreased glucose transport activity observed in
human obesity. Such a defect may impair the function of the
GLUT4 transporter either through decreased activation and/or
translocation to the plasma membrane.
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